AKEBIA THER
NASDAQ: AKBA (Akebia Therapeutics, Inc.)
Kemas kini terakhir: semalam, 8:10AM0.916
0.02 (2.26%)
| Penutupan Terdahulu | 0.896 |
| Jumlah Dagangan | 7,371,754 |
| Harga / Pendapatan (P/E Ke hadapan) | 28.74 |
| Harga / Jualan (P/S) | 1.10 |
| Harga / Buku (P/B) | 10.03 |
| Julat 52 Minggu |
| Margin Keuntungan | -24.51% |
| Margin Operasi (TTM) | 23.85% |
| EPS Cair (TTM) | -0.210 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 75.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 795.72% |
| Nisbah Semasa (MRQ) | 2.23 |
| Aliran Tunai Operasi (OCF TTM) | -34.81 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 12.96 M |
| Pulangan Atas Aset (ROA TTM) | -4.26% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Menaik |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Menaik | |
| Stok | Akebia Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.36 |
|
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 3.59% |
| % Dimiliki oleh Institusi | 38.96% |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |